Bcl-2

[Nature Reviews Cancer] Investigators outline the current state of BH3-mimetic drugs targeting various prosurvival BCL-2 family proteins and discuss emerging data regarding primary and acquired resistance to these agents and approaches that may overcome this.

[Molecular Biology Reports] The authors elucidated the modulation patterns between apoptosis and autophagy following dual inhibition by Akt inhibitor erufosine and Bcl-2 inhibitor ABT-737 in castration-resistant prostate cancer cell lines, PC-3 (Bax+) and DU-145 (Bax−).

[Aging] Cell functional experiments revealed that lncRNA DARS-AS1 participated in enhancing lung adenocarcinoma proliferation, invasion, and migration by inhibiting miR-188-5p.

[Leukemia] Spred1 knockout, regardless if occurred in HSCs or in endothelial cells, increased miR-126 in Lin−Sca-1+c-Kit+, a population enriched in leukemic stem cells (LSCs), resulting in expansion of LSCs, likely through hyperactivation of the MAPK/ERK pathway that augmented Bcl-2 expression and stability.

[Acta Biochimica et Biophysica Sinica] Scientists used Caco-2 cell monolayers as an in vitro model of human intestinal epithelial barrier (IEB) to evaluate the toxicity of chlorothalonil exposure on the structure and function of IEB.

[Aging] Scientists screened rutin (RT) for its activity against osteoarthritis with in vivo and in vitro models of osteoarthritis. Pretreatment of RT decreased the ECM degradation, inhibited expression of TRAF-6 and BCL-2 the NF-κB/MAPK pathway proteins.